

# Michael Xiang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7262473/publications.pdf>

Version: 2024-02-01

34  
papers

1,083  
citations

516561

16  
h-index

414303

32  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1856  
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF- $\kappa$ B to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes. <i>Science Signaling</i> , 2014, 7, ra11.	1.6	146
2	GO PaD: the Gene Ontology Partition Database. <i>Nucleic Acids Research</i> , 2007, 35, D322-D327.	6.5	113
3	Ontology engineering. <i>Nature Biotechnology</i> , 2010, 28, 128-130.	9.4	113
4	Second cancer risk after primary cancer treatment with three-dimensional conformal, intensity-modulated, or proton beam radiation therapy. <i>Cancer</i> , 2020, 126, 3560-3568.	2.0	105
5	<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. <i>Cancer Discovery</i> , 2020, 10, 1826-1841.	7.7	93
6	Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 616-621.	1.6	88
7	Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. <i>Blood</i> , 2016, 128, 1845-1853.	0.6	83
8	Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. <i>Blood Advances</i> , 2019, 3, 4215-4227.	2.5	34
9	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results Medicare analysis. <i>Cancer</i> , 2018, 124, 4486-4494.	2.0	28
10	STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. <i>Cancers</i> , 2014, 6, 958-968.	1.7	23
11	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 1, 1-6.	0.4	23
12	National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma. <i>Gynecologic Oncology</i> , 2019, 152, 599-604.	0.6	22
13	Significant association of brachytherapy boost with reduced prostate cancer-specific mortality in contemporary patients with localized, unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 773-780.	0.2	21
14	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient data Network Meta-analysis from the MARCAP Consortium. <i>European Urology</i> , 2022, 82, 106-114.	0.9	19
15	Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database. <i>Radiotherapy and Oncology</i> , 2020, 143, 101-107.	0.3	18
16	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	3.4	18
17	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
18	Targeting constitutively active <i>STAT3</i> in chronic lymphocytic leukemia: A clinical trial of the <i>STAT3</i> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	2.0	17

#	ARTICLE	IF	CITATIONS
19	Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma. <i>Gynecologic Oncology</i> , 2019, 154, 487-494.	0.6	16
20	Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 969-975.	2.3	16
21	Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. <i>Radiotherapy and Oncology</i> , 2021, 156, 201-208.	0.3	14
22	Prognostic Factors and Treatment Patterns in the Management of Giant Cell Glioblastoma. <i>World Neurosurgery</i> , 2019, 128, e217-e224.	0.7	12
23	Survival after neoadjuvant approaches to gastroesophageal junction cancer. <i>Gastric Cancer</i> , 2020, 23, 175-183.	2.7	12
24	CDK5RAP3 is a co-factor for the oncogenic transcription factor STAT3. <i>Neoplasia</i> , 2020, 22, 47-59.	2.3	11
25	Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e39.	1.0	8
26	Physiological motion of the optic chiasm and its impact on stereotactic radiosurgery dose. <i>British Journal of Radiology</i> , 2019, 92, 20190170.	1.0	3
27	Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 99-104.	0.6	3
28	Landscape of mortality during and within thirty days after non-palliative radiotherapy across eleven major cancer types. <i>Radiotherapy and Oncology</i> , 2022, 167, 308-316.	0.3	2
29	The landscape of mortality during or within 30 days after non-palliative radiotherapy across 11 major cancer types.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6570-6570.	0.8	1
30	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. <i>Blood</i> , 2012, 120, 399-399.	0.6	1
31	Trends and Predictors of Hypofractionated and Intensity-Modulated Radiotherapy for Organ Preservation in Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e94-e103.	0.9	1
32	Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison. <i>Advances in Radiation Oncology</i> , 2022, 7, 100944.	0.6	1
33	Impact of proton radiotherapy on treatment timing in pediatric and adult patients with CNS tumors. <i>Neuro-Oncology Practice</i> , 2020, 7, 626-635.	1.0	0
34	Role of brachytherapy in stage III endometrial cancer treated with adjuvant chemotherapy: Identifying factors predictive of a survival benefit. <i>Brachytherapy</i> , 2021, 20, 701-709.	0.2	0